


We claim:

1. A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to
5 said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than ten minutes after the onset reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.
2. A method according to claim 1, wherein the cardioprotection is provided prior to,
10 during, or following cardiac surgery.
3. A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
- 15 4. A method according to claim 1 wherein the administering of the compound begins at the onset of reperfusion, and continues for a period of more than 30 minutes following the onset of reperfusion.
5. A method according to claim 1, wherein the administering of the compound is
20 continued for a period of more than 70 minutes after the onset of reperfusion.
6. A method according to claim 1, wherein the compound is of the formula



or a pharmaceutically acceptable salt thereof.

7. A method according to claim 1, wherein the compound is administered as a
5 pharmaceutically acceptable salt thereof.

8. A method according to claim 1, wherein the compound administered is contained in a
pharmaceutical composition comprising a pharmaceutically acceptable carrier and a
pharmaceutically effective amount of the compound.


10 9. A method of providing cardioprotection, or protecting against reperfusion injury, or
protecting against ischemic injury, in a patient in need thereof comprising administering to
said patient a pharmaceutically effective amount of a compound having adenosine A1/A2
agonistic activity, beginning at a time 10 minutes or more before the onset of reperfusion, and
15 continuing for a period of more than 30 minutes after the onset of reperfusion.

10. A method according to claim 9, wherein the cardioprotection is provided prior to,
during, or following cardiac surgery.

20 11. A method according to claim 9, wherein the cardioprotection is provided prior to,
during, or following ischemic attack.

12. A method according to claim 9, wherein the administering of the compound is
continued for a period of more than 70 minutes after the onset of reperfusion.

25 13. A method according to claim 9, wherein the compound is of the formula



or a pharmaceutically acceptable salt thereof.

- 5 14. A method according to claim 9, wherein the compound is administered as a
pharmaceutically acceptable salt thereof.
15. A method according to claim 9, wherein the compound administered is contained in a
pharmaceutical composition comprising a pharmaceutically acceptable carrier and a
10 pharmaceutically effective amount of the compound.